Skip to main content
construction release_alert
Profile editing will be unavailable for Scholars@Duke profiles from June 11-24, 2026 as manual profile data entry transitions to Elements. More information about the transition.
cancel

Prognostic Biomarkers of Survival in Ocular Melanoma.

Publication ,  Journal Article
Bobrek, CN; Sarvepalli, SM; Bailey, B; Hadziahmetovic, M
Published in: Ophthalmic Epidemiol
May 25, 2026

PURPOSE: To explore the Surveillance, Epidemiology, and End Results Program (SEER) database in a longitudinal study to determine the factors associated with the risk of death in ocular melanoma. METHODS: Patients with a primary diagnosis of ocular melanoma from the SEER database between 1975 and 2022 were included. Chi-square analysis and independent samples t test were performed. The Kaplan-Meier estimate was also run to determine survival months' variability by primary site. RESULTS: The 2,917 included patients were categorized as "died of ocular melanoma" or "alive or dead of other causes." Age was higher in patients who died from ocular melanoma (60.7 years ±12) compared to those alive or dead of another cause (57.9 years ±13.5; p < 0.001; OR 0.984; 0.977, 0.992; p < 0.001). The primary site of melanoma was also statistically significantly different between groups; conjunctiva (81.7%) and cornea (81.3%) had the highest survival rate, while the lacrimal gland and an overlapping lesion of the eye and adnexa had the highest mortality rates (100% and 73%, respectively; p < 0.001). Survival analysis with Kaplan-Meier estimate showed lacrimal gland and overlapping lesions of eye and adnexa differed in mean months of survival after diagnosis (54 months and 100.8 months, respectively) compared to conjunctiva and ciliary body (264.5 months and 237.5 months, respectively; p < 0.001). CONCLUSION: Age and primary site were associated with mortality from ocular melanoma. Overlapping lesions of the eye and adnexa, unspecified ocular site, and choroid were associated with the highest mortality risk from this melanoma.

Duke Scholars

Published In

Ophthalmic Epidemiol

DOI

EISSN

1744-5086

Publication Date

May 25, 2026

Start / End Page

1 / 5

Location

England

Related Subject Headings

  • Epidemiology
  • 4206 Public health
  • 4202 Epidemiology
  • 3212 Ophthalmology and optometry
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bobrek, C. N., Sarvepalli, S. M., Bailey, B., & Hadziahmetovic, M. (2026). Prognostic Biomarkers of Survival in Ocular Melanoma. Ophthalmic Epidemiol, 1–5. https://doi.org/10.1080/09286586.2026.2678907
Bobrek, Christina N., Swara M. Sarvepalli, Beth Bailey, and Majda Hadziahmetovic. “Prognostic Biomarkers of Survival in Ocular Melanoma.Ophthalmic Epidemiol, May 25, 2026, 1–5. https://doi.org/10.1080/09286586.2026.2678907.
Bobrek CN, Sarvepalli SM, Bailey B, Hadziahmetovic M. Prognostic Biomarkers of Survival in Ocular Melanoma. Ophthalmic Epidemiol. 2026 May 25;1–5.
Bobrek, Christina N., et al. “Prognostic Biomarkers of Survival in Ocular Melanoma.Ophthalmic Epidemiol, May 2026, pp. 1–5. Pubmed, doi:10.1080/09286586.2026.2678907.
Bobrek CN, Sarvepalli SM, Bailey B, Hadziahmetovic M. Prognostic Biomarkers of Survival in Ocular Melanoma. Ophthalmic Epidemiol. 2026 May 25;1–5.

Published In

Ophthalmic Epidemiol

DOI

EISSN

1744-5086

Publication Date

May 25, 2026

Start / End Page

1 / 5

Location

England

Related Subject Headings

  • Epidemiology
  • 4206 Public health
  • 4202 Epidemiology
  • 3212 Ophthalmology and optometry